Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment (HERMOSA-2)
A Phase 1, Open-label, Multiregional, Multicenter, Basket Study Evaluating the Safety and Efficacy of KITE-363, an Autologous Anti-CD19/CD20 CAR T-cell Therapy in Participants With Relapsed/Refractory Autoimmune Neurologic Diseases
This study will have two Phases: Phase 1a and Phase 1b. The goals of this clinical study are to learn more about the study drug KITE-363, by evaluating its safety, tolerability and efficacy in participants with relapsed/refractory autoimmune neurologic diseases.
The primary objectives of this study are:
- To evaluate the safety and tolerability of KITE-363 in participants with autoimmune neurologic diseases
- To determine the recommended dose for Phase 1b
- To evaluate the safety and preliminary efficacy of KITE-363 in participants with autoimmune neurologic diseases
研究概览
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习联系方式
- 姓名:Medical Information
- 电话号码:844-454-5483(1-844-454-KITE)
- 邮箱:medinfo@kitepharma.com
学习地点
-
-
-
Montreal、加拿大、H3T 1E2
- 招聘中
- Jewish General Hospital
-
Montreal、加拿大、H1T 2M4
- 招聘中
- Centre Intégré Universitaire de Sante et Services Sociaux de L'Est de I'lle de Montreal / installation Hopital Maisonneuve-Rosemont
-
Ottawa、加拿大、K1H 8L6
- 招聘中
- The Ottawa Hospital - General Campus
-
-
-
-
New South Wales
-
Sydney、New South Wales、澳大利亚、2139
- 招聘中
- Concord Repatriation General Hospital
-
Westmead、New South Wales、澳大利亚、2145
- 招聘中
- Corner Hawkesbury Road and Darcy Road
-
-
-
-
California
-
Newport Beach、California、美国、92663
- 招聘中
- Hoag Memorial Hospital Presbyterian
-
Palo Alto、California、美国、94304
- 招聘中
- Stanford Neuroscience Health Center
-
-
New York
-
New York、New York、美国、10032
- 招聘中
- Columbia University Irving Medical Center
-
-
Utah
-
Salt Lake City、Utah、美国、84143
- 招聘中
- LDS Hospital - Intermountain Health
-
-
Washington
-
Seattle、Washington、美国、98109
- 招聘中
- Fred Hutchinson Cancer Center
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Key Inclusion Criteria:
-
Age 18 through 65 for relapsing forms of MS, 18 through 75 for progressive forms of MS, above 18 years of age for MG and CIDP.
-
Reproductive status-related eligibility and contraception requirements:
- Individuals must agree to use protocol-specified method(s) of contraception where applicable
Inclusion Criteria for multiple sclerosis (MS):
MS (Relapsing and progressive forms):
- Diagnosed with MS according to the 2017 revision of the McDonald diagnostic criteria
Relapsing forms of MS (relapsing-remitting multiple sclerosis (RRMS), active secondary-progressive multiple sclerosis (aSPMS)):
- Inadequate response to previous therapies is defined as evidence of breakthrough disease activity within 12 months prior to screening while on high efficacy disease-modifying therapy (DMT) OR Inadequate response to previous therapies defined as intolerance to ≥ 2 DMTs due to side effects prohibiting the chronic use of the DMT.
- Expanded Disability Status Scale (EDSS) 0 to 6.0
Progressive forms of MS (primary-progressive multiple sclerosis (PPMS) and non-active secondary-progressive multiple sclerosis (naSPMS)):
- Inadequate response to previous therapies is defined as evidence of disease progression within 12 months prior to screening despite standard of care therapy for naSPMS or despite ocrelizumab, where available, for PPMS
- Absence of clinical relapses for at least 24 months
- No evidence of Gadolinium enhancing (GadE+) on magnetic resonance imaging (MRI) brain at screening or baseline
- EDSS of 3 to 6.5 who are ambulatory
Inclusion Criteria for myasthenia gravis (MG):
- Documentation of autoantibodies against acetylcholine receptor (AChR), muscle-specific kinase (MuSK), or low-density lipoprotein receptor-related protein 4 (LRP4)
- Diagnosis of MG with generalized weakness meeting criteria as defined by the Myasthenia Gravis Foundation of American (MGFA) classification of II- IV at screening
- Myasthenia Gravis Activities of Daily Living (MG-ADL) score ≥ 6 (> 50% of the total score due to non-ocular symptoms)
- Quantitative Myasthenia Gravis (QMG) score ≥ 10
- Inadequate response to previous therapies while taking at least 2 classes of immunosuppressants (ie, steroids, azathioprine (AZA), mycophenolate mofetil (MMF), intravenous immunoglobulin (IVIg), biologics (eg, rituximab, anti-FcRN class, and anti-complement class))
- Thymectomy allowed if completed ≥ 12 months prior to screening
Inclusion Criteria for chronic inflammatory demyelinating polyneuropathy (CIDP):
-
Probable or definite CIDP as defined by the 2010 European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) criteria, relapsing or progressive forms. Individuals with confirmed IgG4 paranodal antibodies (eg, NF155, CNTN1, Caspr1) are eligible if they meet EFNS/PNS 2010 criteria
- For the Phase 1b CIDP cohort, diagnosis will be confirmed by independent adjudication once the adjudication committee is established and operational
-
CIDP Disease Activity Status (CDAS) score ≥ 3 at screening and confirmed at the final pre treatment assessment prior to infusion
-
Inflammatory neuropathy cause and treatment (INCAT) score ≥ 3 at screening and confirmed at one of more protocol-defined baseline assessments during the Extended Screening Period with Observational Run-in; individuals must also continue to meet clinical eligibility criteria at the final pre-treatment assessment prior to infusion
-
Inadequate response to previous therapies despite adequate trial of standard of care therapy (≥ 8-12 weeks at standard dosing with stable regimen of either steroids, IVIg, SCIg, plasmapheresis exchange (PLEX), rituximab or anti-FcRN) and either failure, intolerance, or contraindication to at least one additional standard therapy (ie, steroids, IVIg, subcutaneous immunoglobulin (SCIg), plasmapheresis exchange (PLEX), rituximab, or anti FcRN), unless medically inappropriate OR Unable to tolerate standard of care resulting in discontinuation due to side effects, with ongoing disease activity
-
Except for nodal/paranodal CIDP, historical documentation of objective improvement in the past 24 months while on IVIg, SCIg, PLEX, or anti-FcRN OR Historical documentation of objective disease worsening in the past 24 months when IVIg, SCIg, PLEX, or anti-FcRN has been reduced or interrupted
Key Exclusion Criteria:
- History or presence of central nervous system (CNS) or peripheral nervous system disorders before enrollment that may impact cognition, strength, or cause weakness
- History of autologous or allogeneic stem cell transplant and/or organ transplant
- History of hemophagocytic lymphohistiocytosis (HLH) or macrophage activation syndrome (MAS)
Exclusion Criteria for MS:
- Cohort 1 or 2; inability to complete 9-hole Peg Test (9-HPT) in < 240 seconds and Timed 25 foot Walk (T25FW) < 150 seconds
- History of hypersensitivity to parenteral administration of gadolinium-based contrast agents
- Any renal condition that would preclude the administration of gadolinium (for the relapsing forms of MS and progressive forms of MS)
- Any contraindication to lumbar puncture (LP) (for the relapsing forms of MS and progressive forms of MS)
Exclusion Criteria for MG:
- Current myasthenic crisis not effectively controlled within 2 weeks before enrollment
- Thymectomy performed within 12 months of baseline
Exclusion Criteria for CIDP:
- Pure sensory CIDP and focal CIDP
- Polyneuropathy of other causes
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:顺序分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Phase 1a: KITE-363 (Dose Escalation) With Lymphodepleting Chemotherapy
Participants with relapsing forms of multiple sclerosis (RMS), progressive forms of multiple sclerosis (PMS), myasthenia gravis (MG), and/or chronic inflammatory demyelinating polyneuropathy (CIDP) will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by infusion of KITE-363 chimeric antigen receptor (CAR) transduced autologous T cells at a single dose level, with different participants receiving sequential dose-escalation levels to find the Phase 1b recommended dose. |
Administered intravenously Administered intravenously A single infusion of CAR-transduced autologous T cells administered as intravenous infusion. |
|
实验性的:Phase 1a: KITE-363 (Dose Escalation) Without Lymphodepleting Chemotherapy
Participants with RMS, PMS, MG, and/or CIDP will receive infusion of KITE-363 CAR transduced autologous T cells at a single dose level, with different participants receiving sequential dose-escalation levels to find the Phase 1b recommended dose. |
A single infusion of CAR-transduced autologous T cells administered as intravenous infusion. |
|
实验性的:Phase 1b: KITE-363 (Dose Expansion)
Participants with RMS, PMS, MG, and/or CIDP will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed Phase 1a recommended dose of KITE-363 CAR T cells. |
Administered intravenously Administered intravenously A single infusion of CAR-transduced autologous T cells administered as intravenous infusion. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
1a期:输注KITE-363后出现剂量限制性毒性(DLT)的受试者百分比
大体时间:最多28天
|
最多28天
|
|
|
1b期:复发型多发性硬化(RRMS和aSPMS):第12周MRI检查中新发和/或扩大的T2病灶数量
大体时间:第12周
|
第12周
|
|
|
Phase 1a: Percentage of Participants Experiencing Treatment-emergent Adverse Event (TEAEs)
大体时间:Up to 3 years
|
Up to 3 years
|
|
|
Phase 1b: (All Cohorts) Percentage of Participants Experiencing TEAEs
大体时间:Up to 3 years
|
Up to 3 years
|
|
|
Phase 1b: Relapsing Forms of MS (RRMS) and Active Secondary-progressive Multiple Sclerosis (aSPMS): Number of New T1 Gadolinium Enhancing (GadE+) Lesions on Magnetic Resonance Imaging (MRI) at Week 12
大体时间:Week 12
|
This will be reported in participants with relapsing forms of Multiple Sclerosis MS (RRMS) and (aSPMS). |
Week 12
|
|
Phase 1b: Progressive Forms of MS (PPMS) and Non-active Secondary-progressive Multiple Sclerosis (naSPMS): Time to Onset of Confirmed Disability Progression Over 12 Weeks (CDP-12)
大体时间:Up to 3 years
|
Up to 3 years
|
|
|
Phase 1b: Myasthenia Gravis (MG): Proportion of Participants of MG Activities of Daily Living (MG-ADL) Responders
大体时间:Up to 3 years
|
The MG-ADL is a scale to measure the functional impact of MG on daily activities. The total score ranges from 0 to 24, with higher scores indicating greater disability and disease burden. |
Up to 3 years
|
|
Phase 1b: CIDP: Proportion of Participants with a ≥ 2 Points Improvement from Baseline in aINCAT Score at Week 24, in the Absence of CIDP Rescue Therapy or Initiation of New Maintenance Immunomodulatory Therapy
大体时间:Up to 3 years
|
Clinical improvement will be analyzed using adjusted inflammatory neuropathy cause and treatment (aINCAT) scale. The INCAT score is a clinician administered tool used to assess functional disability in participants with chronic inflammatory demyelinating polyneuropathy (CIDP). The total scores range from 0 to 10, higher scores indicating greater disability and lower score would indicate clinical improvement. |
Up to 3 years
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
血液中T细胞水平
大体时间:最多 2 年
|
最多 2 年
|
|
|
药代动力学:血液中嵌合抗原受体(CAR)T细胞水平
大体时间:最长2年
|
最长2年
|
|
|
药效学参数:血液中B细胞水平
大体时间:最长2年
|
最长2年
|
|
|
药效动力学参数:血液中疾病特异性生物标志物和自身抗体水平
大体时间:最长2年
|
最长2年
|
|
|
血液中针对 KITE-363 CAR T 细胞抗体阳性的参与者比例
大体时间:最长2年
|
最长2年
|
|
|
Relapsing forms of MS (RRMS and aSPMS): Annual Relapse Rate
大体时间:Up to 3 years
|
Proportion of participants with annual relapse. |
Up to 3 years
|
|
Relapsing Forms of MS (RRMS and aSPMS): Proportion of Participants With CDP-12
大体时间:Up to 3 years
|
Up to 3 years
|
|
|
Relapsing Forms of MS (RRMS and aSPMS): Proportion of Participants With CDP-24
大体时间:Up to 3 years
|
Up to 3 years
|
|
|
Relapsing Forms of MS (RRMS and aSPMS): Time to Onset of CDP-12
大体时间:Up to 3 years
|
Up to 3 years
|
|
|
Relapsing Forms of MS (RRMS and aSPMS): Time to Onset of CDP-24
大体时间:Up to 3 years
|
Up to 3 years
|
|
|
Progressive forms of MS (PPMS and naSPMS): Proportion of Participants with No Evidence of Disease Activity (NEDA)
大体时间:Up to 3 years
|
Up to 3 years
|
|
|
Relapsing Forms of MS (RRMS and aSPMS): Change From Baseline in Expanded Disability Status Scale (EDSS) Score Over Time
大体时间:Up to 3 years
|
EDSS is scale used to measure disability and disease progression in participants with MS. It ranges from 0 (normal neurological exam) to 10 (death due to MS) in 0.5-point increments. |
Up to 3 years
|
|
Relapsing Forms of MS (RRMS and aSPMS): Change From Baseline in Timed 25-foot Walk (T25FW) Score Over Time
大体时间:Up to 3 years
|
The T25FW is a performance-based measure used in people with MS to assess walking speed and mobility. Lower times indicate better walking ability, while longer times reflect greater impairment. |
Up to 3 years
|
|
Relapsing Forms of MS (RRMS and aSPMS): Change From Baseline in 9-hole Peg Test Dominant/Non-dominant (9-HPT D/ND) Score Over Time
大体时间:Up to 3 years
|
The 9-HPT assesses hand dexterity and fine motor function by timing how long it takes a participant to place and remove nine pegs from a board. Faster times indicate better function, while slower times reflect greater disability. |
Up to 3 years
|
|
Relapsing Forms of MS (RRMS and aSPMS): Change From Baseline in Symbol Digit Modalities Test (SDMT) Score Over Time
大体时间:Up to 3 years
|
SDMT is a performance-based cognitive assessment to measure information processing speed. The score is the number of correct responses completed in the time limit, with higher scores indicating better cognitive processing speed. |
Up to 3 years
|
|
Progressive Forms of MS (PPMS and naSPMS): Proportion of Participants with CDP-12
大体时间:Up to 3 years
|
Up to 3 years
|
|
|
Progressive Forms of MS (PPMS and naSPMS): Proportion of Participants with CDP-24
大体时间:Up to 3 years
|
Up to 3 years
|
|
|
Progressive forms of MS (PPMS and naSPMS): Time to Onset of CDP-24
大体时间:Up to 3 years
|
Up to 3 years
|
|
|
Progressive forms of MS (PPMS and naSPMS): Number of new and Enlarging T2 Lesions on MRI
大体时间:Up to 3 years
|
Up to 3 years
|
|
|
Relapsing forms of MS (RRMS and aSPMS): Percentage of Participants With NEDA
大体时间:Up to 3 years
|
Up to 3 years
|
|
|
Progressive forms of MS (PPMS and naSPMS): Change From Baseline in EDSS Over Time
大体时间:Up to 3 years
|
EDSS is scale used to measure disability and disease progression in participants with MS. It ranges from 0 (normal neurological exam) to 10 (death due to MS) in 0.5-point increments. |
Up to 3 years
|
|
Progressive forms of MS (PPMS and naSPMS): Change From Baseline in T25FW Over Time
大体时间:Up to 3 years
|
The T25FW is a performance-based measure used in people with MS to assess walking speed and mobility. Lower times indicate better walking ability, while longer times reflect greater impairment. |
Up to 3 years
|
|
Progressive forms of MS (PPMS and naSPMS): Change From Baseline in 9-HPT D/ND Over Time
大体时间:Up to 2 years
|
The 9-HPT assesses hand dexterity and fine motor function by timing how long it takes a participant to place and remove nine pegs from a board. Faster times indicate better function, while slower times reflect greater disability. |
Up to 2 years
|
|
Progressive forms of MS (PPMS and naSPMS): Change From Baseline in SDMT Over Time
大体时间:Up to 3 years
|
SDMT is a performance-based cognitive assessment to measure information processing speed. The score is the number of correct responses completed in the time limit, with higher scores indicating better cognitive processing speed. |
Up to 3 years
|
|
MG: Proportion of Participants With at Least a 2-Point or 5 Point Improvement in MG-ADL Score up to Week 24
大体时间:Up to 24 weeks
|
The MG-ADL is a scale to measure the functional impact of MG on daily activities. The total score ranges from 0 to 24, with higher scores indicating greater disability and disease burden. |
Up to 24 weeks
|
|
MG: Change From Baseline in MG-ADL Score at Week 24
大体时间:Baseline, Week 24
|
The MG-ADL is a scale to measure the functional impact of MG on daily activities. The total score ranges from 0 to 24, with higher scores indicating greater disability and disease burden. |
Baseline, Week 24
|
|
MG: Proportion of Participants With Minimal Symptom Expression (MG-ADL Score of 0 or 1 Point)
大体时间:Up to 3 years
|
The MG-ADL is a scale to measure the functional impact of MG on daily activities. The total score ranges from 0 to 24, with higher scores indicating greater disability and disease burden. |
Up to 3 years
|
|
MG: Proportion of Participants With at Least a 3-point or 5-point Improvement in Medical Research Council (QMG) Score up to Week 24
大体时间:Baseline, Week 24
|
The QMG test is a standardized quantitative strength scoring system developed specifically for MG. The total QMG score is the sum of the scores for 13 items, with a possible maximum score of 39. A higher score indicates more severe disease involvement, while a lower score suggests less functional impairment. |
Baseline, Week 24
|
|
MG: Change From Baseline in QMG Score to Week 24
大体时间:Baseline, Week 24
|
The QMG test is a standardized quantitative strength scoring system developed specifically for MG. The total QMG score is the sum of the scores for 13 items, with a possible maximum score of 39. A higher score indicates more severe disease involvement, while a lower score suggests less functional impairment. |
Baseline, Week 24
|
|
MG: Proportion of Participants With at Least a 3-Point Improvement in MG-C Score up to Week 24
大体时间:Baseline, Up to 24 weeks
|
MG-C scale is a tool that measures disease severity in MG. The total score ranges from 0 to 50, with higher scores indicating greater impairment. |
Baseline, Up to 24 weeks
|
|
Change From Baseline in MG-C Scale Score at Week 24
大体时间:Baseline, Week 24
|
MG-C scale is a tool that measures disease severity in MG. The total score ranges from 0 to 50, with higher scores indicating greater impairment. |
Baseline, Week 24
|
|
MG: Number of Participants With Changes in Myasthenia Gravis Foundation of American Post-Intervention Status (MGFA-PIS), Including Minimal Manifestation, Complete Stable Remission, Pharmacologic Remission
大体时间:Up to 3 years
|
The MGFA-PIS is a standardized classification system which categorizes outcomes into distinct states such as complete stable remission (CSR), pharmacologic remission (PR), minimal manifestations (MM), improved, unchanged, worse, and exacerbation. CSR indicates no symptoms or signs for at least one year without therapy, while MM reflects minimal weakness without functional limitation. |
Up to 3 years
|
|
CIDP: Proportion of Participants With a ≥ 1-point Improvement from Baseline in aINCAT Score at Week 24, in the Absence of CIDP Rescue Therapy or Initiation of New Maintenance Immunomodulatory Therapy
大体时间:Week 24
|
Clinical improvement will be analyzed using INCAT scale. The INCAT score is a clinician administered tool used to assess functional disability in participants with CIDP. The total scores range from 0 to 10, higher scores indicating greater disability and lower score would indicate improvement. |
Week 24
|
|
Proportion of Participants With a ≥ 2-point Improvement from Baseline in aINCAT Score at Week 24
大体时间:Week 24
|
Clinical improvement will be analyzed using INCAT scale. The INCAT score is a clinician administered tool used to assess functional disability in participants with CIDP. The total scores range from 0 to 10, higher scores indicating greater disability and lower score would indicate improvement. |
Week 24
|
|
Proportion of Participants Without aINCAT Deterioration and Without Requirement for CIDP Rescue or Maintenance Therapy Through Week 24
大体时间:Up to Week 24
|
Up to Week 24
|
|
|
Proportion of Participants With ≥ 1-point Improvement in INCAT Lower Limb Score from Baseline to Week 24, in the Absence of CIDP Rescue Therapy or Initiation of New Maintenance Immunomodulatory Therapy
大体时间:Baseline, up to Week 24
|
Clinical improvement will be analyzed using INCAT scale. The INCAT score is a clinician administered tool used to assess functional disability in participants with CIDP. The total scores range from 0 to 10, higher scores indicating greater disability and lower score would indicate improvement. |
Baseline, up to Week 24
|
|
Proportion of Participants Transitioning from INCAT Lower Limb score ≥ 3 (Assistive Device) to ≤ 2 (Independent Ambulation) from Baseline to Week 24, in the Absence of CIDP Rescue Therapy or Initiation of New Maintenance Immunomodulatory Therapy
大体时间:Baseline, up to Week 24
|
The INCAT score is a clinician administered tool used to assess functional disability in participants with CIDP. The total scores range from 0 to 10, higher scores indicating greater disability and lower score would indicate improvement. |
Baseline, up to Week 24
|
|
CIDP: Time to First aINCAT Deterioration
大体时间:Up to 3 years
|
INCAT is a clinician-administered tool used to assess functional disability in participants with CIDP. The total score ranges from 0 to 10, where higher scores indicate greater disability and lower score would indicate clinical improvement. |
Up to 3 years
|
|
CIDP: Proportion of Participants With Evidence of Clinical Improvement
大体时间:Up to week 24
|
Clinical improvement will be analyzed using inflammatory Rasch-built overall disability scale (I-RODS) scale. I-RODS is a scale that assesses activity and participation limitations in people with CIDP. The score ranges from 0 to 48, with higher scores indicating better functional ability. |
Up to week 24
|
|
CIDP: Change From Baseline Over Time in Adjusted INCAT Score
大体时间:Up to 3 years
|
INCAT is a tool used to assess functional disability in participants with CIDP. The total score ranges from 0 to 10, where higher scores indicate greater disability. |
Up to 3 years
|
|
CIDP: Change From Baseline Over Time in 24-Item I-RODS Score
大体时间:Up to 3 years
|
I-RODS is a scale that assesses activity and participation limitations in people with CIDP. The score ranges from 0 to 48, with higher scores indicating better functional ability. |
Up to 3 years
|
|
CIDP: Change From Baseline Over Time in Medical Research Council (MRC) Sum Score
大体时间:Up to 3 years
|
MRC Sum Score is a measure to assess muscle strength for people with CIDP. The score ranges from 0 to 60. Higher scores indicate better muscle strength, while lower scores reflect greater weakness. |
Up to 3 years
|
|
CIDP: Change From Baseline Over Time in Timed Up and Go (TUG) Score
大体时间:Up to 3 years
|
TUG test is a measure of mobility, balance, and fall risk. The score is recorded in seconds; shorter times indicate better mobility, while longer times suggest impaired balance or gait. |
Up to 3 years
|
|
CIDP: Change From Baseline Over Time in Mean Grip Strength
大体时间:Up to 3 years
|
Mean Grip Strength is a quantitative measure of hand and forearm muscle strength. Higher values indicate better muscle strength, while lower values reflect weakness or functional impairment. |
Up to 3 years
|
|
Proportion of Participants With European Quality of Life 5-Dimension 5-Level Questionnaire (EQ-5D-5L)
大体时间:Up to 3 years
|
The EQ-5D-5L is a generic measure of health status captured on the day of assessment. Two components comprise the EQ-5D-5L: the EQ-5D descriptive system and the EQ visual analog scale (VAS). The descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and is divided into 5 levels of severity: "no problems," "slight problems," "moderate problems," "severe problems," and "extreme problems." The EQ-5D-5L VAS is a vertical VAS for recording self-rated current HRQoL, and it ranges from 0, described as "the worst health you can imagine," to 100, described as "the best health you can imagine." EQ-5D-5L will be scored according to the published administration and scoring manual. |
Up to 3 years
|
|
Proportion of Participants With Chronic Acquired Polyneuropathy Patient-reported Index (CAP-PRI)
大体时间:Up to 3 years
|
The CAP-PRI is a tool developed to assess the impact of chronic acquired polyneuropathy on participant's quality of life, capturing both physical and psychological symptoms from the participant's perspective. The scoring of the CAP-PRI is typically based on how participants rate their symptoms and overall health across various dimensions, such as sensory symptoms, motor function, pain, emotional well-being, and fatigue. Each dimension of the CAP-PRI is scored separately, and the results are summed up to give an overall score for the participant, with higher scores indicating greater severity or a worse quality of life. Each domain typically uses a Likert scale or similar ordinal scale, where participants rate their experience or symptoms on a scale from 0 to 5. |
Up to 3 years
|
|
Proportion of Participants With Rasch-Transformed Fatigue Severity Scale (RT-FSS)
大体时间:Up to 3 years
|
The RT-FSS or FSS-7 is a refined version of the original 9-item Fatigue Severity Scale (FSS-9) designed to improve accuracy in measuring fatigue, particularly in participants with immune-mediated neuropathies. The original 7-point Likert scale was collapsed into a 4-point response category for the remaining items to fulfill strict linearity requirements. It is a linearly weighted scale, meaning its scores provide a more precise, interval-level measurement rather than just an ordinal ranking. It was specifically validated for conditions like Guillain-Barré syndrome and CIDP. This modified scale provides a more stable test-retest reliability. The scale is used to distinguish between different levels of fatigue impact on daily activities, though it may have a ceiling effect for patients with extremely severe symptoms. |
Up to 3 years
|
|
Pharmacodynamics Parameters: Levels of Cytokines and Chemokines in Blood
大体时间:Up to 2 years
|
A panel of inflammatory, immuno-modulatory and effector molecules, including cytokines and chemokines, will be measured as units of concentration in serum (e.g. pg/ml) using ligand-based immunoassays such as MSD, Ella and O-link. |
Up to 2 years
|
合作者和调查者
调查人员
- 研究主任:Kite Study Director、Kite, A Gilead Company
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- KT-US-728-0204
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.